Clinical Trials Logo

Blindness clinical trials

View clinical trials related to Blindness.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06262152 Recruiting - Blindness Clinical Trials

Sleep Profile of Patients With Septo-optic Dysplasia

Start date: December 20, 2023
Phase:
Study type: Observational

The aim of this study is to evaluate sleep of patients with septo-optic dysplasia compared to patients with an isolated disorder of peripheral visual system and patients with corpus callosum agenesis since both visus defict and agenesis of corpus callosum might be present SOD but associated to other features / structural and functional anomalies. Included patients and their caregivers will be asked to compile standardize sleep questionnaires and a sleep screening through an interview will be scheduled. Patients will be asked to wear an actigraph on their non-dominant hand wrist for 7 days.

NCT ID: NCT06237829 Recruiting - Blindness Clinical Trials

Testing Tactile Aids With Blind Subjects

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. These materials are commonly used in household products, but have not yet been used to enrich tactile aids. Successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. Other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.

NCT ID: NCT06088992 Recruiting - Clinical trials for Leber Congenital Amaurosis

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Start date: January 10, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.

NCT ID: NCT06064565 Recruiting - Clinical trials for Leber Congenital Amaurosis

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT)

Start date: January 10, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.

NCT ID: NCT06027216 Recruiting - Blind Right Eye Clinical Trials

Multiplexing Prism Fitting for Field Expansion of Monocular Vision

Start date: December 27, 2023
Phase: N/A
Study type: Interventional

The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators are testing a simplified design and fitting protocol to provide field expansion for individuals with acquired monocular vision.

NCT ID: NCT05906953 Recruiting - Clinical trials for Leber Congenital Amaurosis

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

Start date: October 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.

NCT ID: NCT05694247 Recruiting - Corneal Disease Clinical Trials

Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness

Start date: March 2024
Phase: N/A
Study type: Interventional

A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness

NCT ID: NCT05377853 Recruiting - Blindness Clinical Trials

Advanced Spatiomotor Rehabilitation for Navigation in Blindness & Visual Impairment

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

One of the most challenging tasks for blind and visually impaired individuals is navigation through a complex environment. The goal of the present multidisciplinary study is to increase spatial-cognition abilities in people who are blind or visually impaired through training with the previously-developed Cognitive-Kinesthetic Rehabilitation Training to improve navigation, and to investigate the resultant neuroplastic brain reorganization through multimodal brain imaging. In accordance with National Eye Institute (NEI) strategic goals, this multidisciplinary project will promote the development of well-informed new approaches to navigational rehabilitation, memory enhancement and cross-modal brain plasticity to benefit 'cutting edge' fields of mobile assistive technologies, vision restoration and memory facilitation for the aging brain.

NCT ID: NCT05203939 Recruiting - Clinical trials for Retinitis Pigmentosa

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

Start date: January 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.

NCT ID: NCT05188703 Recruiting - Clinical trials for Diabetic Retinopathy

Patient Navigator Intervention for Diabetic Retinopathy

SEEN
Start date: July 25, 2022
Phase: N/A
Study type: Interventional

This is a pilot study of a patient navigator intervention for people living with diabetes and at high risk of diabetic blindness. The investigators are assessing the feasibility and acceptability of the intervention in preparation for a clinical trial.